Event Type
Disclosure
Mandatory
Variant
8-K
. Entry Into a Material Definitive Agreement On December 17, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into Amen
disclosure, including Exhibits 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, except
Financial Statements and Exhibits (d) Exhibits. The following exhibits are filed herewith. Exhibit Number Description 10.1 Amendment No. 2 To Agreement for GSK